New and Noteworthy | Flatiron Health | Comparative effectiveness

Showing 9 of 0 results

Treatment duration and subsequent treatments of first-line CDK4/6i plus aromatase inhibitor for HR+/HER2- metastatic breast cancer in US routine clinical practice
ESMO
Key considerations for assessing real-world comparative effectiveness in the context of the Drug Price Negotiation program: A case study of pembrolizumab
PharmaEconomics
- Comparative effectiveness
- Non-small cell lung cancer
Real-world progression-free survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR-positive/HER2-negative metastatic breast cancer in United States routine clinical practice
ESMO Open
Crossing borders: the need for empirical evidence of real-world evidence transportability in oncology
Journal of Comparative Effectiveness Research
- Comparative effectiveness
- HTA and market access
The BEV1L study: do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?
Cancer
Using regression discontinuity in time design for real-world comparative effectiveness: A case study for the second-line use of pembrolizumab in advanced non-small cell lung cancer
ISPOR 2025
Comparative overall survival of CDK4/6 inhibitors plus an aromatase inhibitor in HR+/HER2− metastatic breast cancer in the US real-world setting
ESMO Open
Effectiveness of PARP inhibitor maintenance therapy in advanced ovarian cancer by BRCA1/2 and HRD signature in real-world practice
ASCO Annual Meeting
Emulating randomized controlled trials with hybrid control arms in oncology: a case study
Clinical Pharmacology & Therapeutics